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The challenge of associated intramural hematoma
with endovascular repair for penetrating ulcers of
the descending thoracic aorta
Himanshu J. Patel, MD,a David M. Williams, MD,b Gilbert R. Upchurch Jr, MD,a
Narasimham L. Dasika, MD,b and G. Michael Deeb, MD,a Ann Arbor, Mich
Background: The presence of penetrating aortic ulcers (PAUs) of the descending thoracic aorta has been associated with
a poor long-term prognosis. Although early results have suggested acceptable outcomes for thoracic endovascular aortic
repair (TEVAR) for PAU, few studies have described the late outcomes of this approach.
Methods: From 1993 to 2009, 37 patients (43.2% male; mean age, 72 years) underwent TEVAR for PAU. Associated
intramural hematoma was present in 19. Comorbidities included hypertension in 31, chronic obstructive pulmonary
disease in 16, coronary artery disease in 22, and renal failure (mean preoperative creatinine, 1.4 mg/dL). Urgent or
emergent indications were identified in 22 patients (59.5%), including presentation with rupture in 15 (40.5%).
Results: TEVAR was successfully performed in all patients. Arch repair was performed in 14 and total descending repair
in 13. Concomitant procedures included coronary artery bypass grafting (CABG) and total arch debranching in one
patient electively presenting with an asymptomatic PAU. Early morbidity included stroke (5.4%), temporary paraplegia
(5.4%), and need for dialysis (2.7%). In-hospital or 30-day mortality was seen in two patients (5.4%). By Kaplan-Meier
analysis, median survival was 89.8 months. Independent predictors of late mortality included urgent or emergent
presentation (odds ratio, 14.7; P  .007). Actuarial freedom from TEVAR treatment failure (ie, need for open or
endovascular aortic reintervention, aortic rupture, or aortic-related death) was 81.6% 7.8% at 5 years. Analysis stratified
by type of pathology (PAU vs PAU and intramural hematoma) showed no significant baseline differences in age,
comorbidities, or extent of repair. By Kaplan-Meier analysis, however, presentation with PAU and intramural hematoma
was associated with an increased risk for TEVAR treatment failure (P  .033).
Conclusions: TEVAR can be safely accomplished for patients presenting with PAU. The presence of associated intramural
hematoma may adversely affect the late outcomes of therapy, highlighting the need for careful planning, prudent
balancing of the benefits of immediate vs delayed treatment of the fragile aortic wall, and the imperative nature of
attentive follow-up in patients with PAU. (J Vasc Surg 2010;51:829-35.)Penetrating aortic ulcers (PAUs) are frequently a local-
ized pathologic entity and were first identified in the setting
of significant widespread aortic atherosclerotic burden.1,2
Stanson et al2 called attention to the virulence of PAU and
its association with atherosclerosis in 1986, but the natural
history continues to be debated.1-6 Despite differing ap-
proaches to PAU, the localized nature of this disease invites
an endovascular solution.
We, and others, have recently documented early suc-
cess of thoracic endovascular aortic repair (TEVAR) for
PAU.7-11 Late results of this approach remain poorly de-
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doi:10.1016/j.jvs.2009.11.050fined, however. Because PAU often presents with intramu-
ral hematoma (IMH), a localized therapeutic approachmay
result in the placement of endografts in potentially unstable
landing zones, thus compromising late outcomes. We un-
dertook this analysis of our 16-year experience with
TEVAR to identify late outcomes with endovascular ther-
apy for PAU.
METHODS
The University of Michigan Hospitals Investigational
Review Board (IRB No. 2003-0128) approved this study.
Requirements for informed patient consent were waived.
Data from all patients who underwent endovascular
repair of a PAU in the thoracic aorta at the University of
Michigan Hospitals between 1993 and 2009 were retro-
spectively analyzed. The diagnosis of PAUwas made by the
presence of an ulcerated lesion extending through the
aortic intima with or without the presence of IMH, as
documented by preoperative computed tomography (CT)
imaging. If the latter existed, characteristics we previously
described were used to differentiate PAU from intercostal
artery pseudoaneurysms.12
Indications for intervention included (1) rupture, (2)
symptoms, or (3) the presence or formation of a saccular
aneurysm of any size in the asymptomatic patient. A PAU
without these criteria, with or without IMH, was not
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thology was treated with maximum medical therapy. If an
indication for operation was identified, all patients were
evaluated for open thoracic aortic repair initially by a tho-
racic surgeon with specific expertise in thoracic aortic re-
construction. If the patient was prospectively deemed a
high-risk candidate for traditional open repair, had favor-
able anatomic characteristics for endovascular repair (eg,
mid-descending PAU), or preferred an endovascular ap-
proach, a collaborative multidisciplinary team consisting of
thoracic or vascular surgeons, or both, and interventional
radiologists assessed the patient’s suitability for TEVAR.
Endograft sizing was performed with the use of imag-
ing techniques, as needed, including spiral CT, with or
without three-dimensional reconstruction, intravascular ul-
trasound, and calibrated angiography. The stent grafts se-
lected were oversized by 5% to 10% of the diameter of the
aorta, and the sizing techniques were independent of the
type of endograft used.
Whether an IMH was present or not, the aortic diam-
eter was chosen as that including the lumen as well as a
partial thickness (often 50%) of the wall. Understanding the
long time interval of the study period, including the “learn-
ing curve,” this sizing strategy likely evolved over time.
However, in no instance was the outer diameter chosen to
avoid aggressive oversizing, particularly in the setting of an
IMH. Similarly, a luminal diameter was not chosen, be-
cause in our experience and as others have reported, the
lumen often contracts in size during the initial IMH event
Table I. Demographics, comorbidities, and procedural
details of the study cohort that underwent univariate analysis
Variables No. (%) or mean  SD
Demographics
TEVAR cohort 37 (100)
Age, y 72.2  10.6
Male sex 16 (43.2)
Maximum aortic dimension, cm 5.0  1.4
Comorbidities
Coronary artery disease 22 (59.5)
History of congestive heart failure 3 (8.1)
COPD 16 (43.2)
Diabetes 3 (8.1)
Hypertension 31 (83.8)
Pre-op creatinine, mg/dL 1.4  2.1
Prior AAA repair 4 (10.8)
PVOD 8 (21.6)
History of tobacco abuse 20 (54.1)
Treated aortic segments
Arch aorta 14 (37.8)
Total descending aorta 13 (35.1)
Procedural details
Elective status 15 (40.5)
Aortic rupture 15 (40.5)
AAA, Abdominal aortic aneurysm; CHF, congestive heart failure; COPD,
chronic obstructive pulmonary disease; PVOD, peripheral vascular occlusive
disease; SD, standard deviation; TEVAR, thoracic endovascular aneurysm
repair.and then enlarges as the IMH resolves.13TEVAR was then performed as previously described.7
Understanding the learning curve during this 16-year pe-
riod, important technical considerations included limiting
balloon dilation of the stent grafts to overlap zones rather
than in proximal and distal landing zones in the setting of
an IMH. Technical success of TEVAR was considered
placement of a patent endoprosthesis and exclusion of the
target aortic pathology without evidence of type I or III
endoleaks.
Postoperative management for prevention of spinal
cord ischemia for endovascular repairs was conducted
Fig 1. Cumulative survival is shown for patients undergoing elec-
tive (solid line) and urgent or emergent (dashed line) thoracic
endovascular aneurysm repair. Seven year actuarial survival was
84.4% 10.2% for elective operation vs 46.2% 11.4% for urgent
or emergent operation. Operative status was also identified as an
independent risk factor for late all cause mortality on multivariate
analysis (P  0.006).
Fig 2. Kaplan-Meier analysis shows freedom from aortic reinter-
vention, rupture, or aortic-related death during the 84-month
follow-up.according to standardized protocols, as previously de-
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lumbar drains, patients received spinal drainage for similar
indications and included those patients who needed repair
beyond the proximal third of the descending aorta. Lumbar
drains were also preferentially placed in those patients with
previous infrarenal aortic repair.
Our preference for subclavian artery revascularization
evolved over time. From 1993 to 2005, we used a selective
approach to preemptive left-carotid-to-subclavian artery
bypass in the setting of a prior left internal mammary bypass
graft, a dominant left vertebral artery, or a vertebral artery
arising from the arch aorta. Since 2005, we now routinely
perform revascularization, when feasible, to minimize the
risk of paraplegia and stroke.
The primary outcome of this study was all-cause mor-
tality. Data were collected from clinic visit notes, hospital
records, and imaging studies. Death was verified by inter-
rogation of the National Death Index. Follow-up for the
primary outcome was 100% complete as of August 2009 at
a mean of 32.6  42.9 months (range, 0-191 months).
Statistical analysis. Data were analyzed using SPSS
software (SPSS Inc, Chicago, Ill). Dichotomous vari-
ables were evaluated using 2 analysis and continuous
variables using one-way analysis of variance. Multivariate
models (binary logistic regression) were constructed using
a forward conditional process to identify factors that were
independently associated with each of the outcomes of
interest. Models were tested for goodness of fit using the
Table II. New or persistent endoleaks and late thoracic ao
Pt Age, y Pathology Extent of TEVAR cove
1 71 PAU/IMH Total descending aort
5 71 PAU Total descending aort
10 79 PAU with ruptured
mycotic aneurysm
Distal thoracic aorta
11 88 PAU/IMH with rupture Prox descending aorta
13 68 PAU/IMH Distal arch and prox
descending aorta
15 73 PAU/IMH Total descending aort
16 76 PAU Prox two-thirds
descending aorta
18 74 PAU/IMH with rupture Distal arch and prox
descending aorta
24 85 PAU/IMH with rupture Distal arch and prox
descending aorta
CT, Computed tomography; DTAR, descending thoracic aneurysm repai
thoracic aortic endovascular repair.
aPatient died from complications of cirrhosis before repeat TEVAR.Hosmer-Lemeshow statistic. Factors used in the multivar-iate analysis included those with a significance value of P
0.1 on the univariate analysis. Survival was analyzed by
Kaplan-Meier methods, with differences in survival assessed
with log-rank testing. All results with P .05 were consid-
ered statistically significant.
RESULTS
The entire cohort comprised 37 patients (43.2% male)
who were a mean age of 72.2 10.6 years. Demographics
and comorbidities are listed in Table I. The procedure was
considered elective in 15 patients (40.5%). Median postop-
erative length of stay was 8 days.
Technical TEVAR success was achieved in all patients.
Devices used included 5 custom-fabricated, 24 TAG (WL
Gore, Flagstaff Ariz), 7 Talent (Medtronic, Minneapolis
Minn) or 1 TX2 (Cook, Bloomington Ind). Device delivery
was through a transfemoral approach in 31 patients and a
retroperitoneal iliac artery approach using a conduit in 5.
The remaining patient underwent TEVAR through the
ascending aorta at the time of an arch debranching proce-
dure. To achieve sufficient proximal landing zones, subcla-
vian arterial coverage was needed in 14 patients; 10 had
undergone either prior or concomitant left carotid to left
subclavian arterial bypass. One of these patients required
coverage into the ascending aorta for a large aneurysm just
distal to the origin of the innominate artery. He was found
to have concomitant left main coronary artery disease and
therefore underwent concomitant off-pump coronary ar-
events
Endoleak or aortic event Outcome
Presentation at 1-mo CT scan with back
pain and tear at prox landing zone;
underwent DTAR at that time
Alive at 191
mo
Aortic growth and prox endoleak at 6-year
CT scan required repeat TEVAR
Alive at 106
mo
Persistent type I or II endoleak at
predischarge CT scan; no imaging
follow-up thereafter
Died at 4 mo
Thoracic aortic rupture on night of TEVAR Died on first
postoperative
night
Tear at prox landing zone in midarch at
12-mo CT scan requiring prox TEVAR
extension; again tore at that proximal
landing zone and underwent DTAR 16
mo later
Alive at 80 mo
Tear at prox landing zone at 3 mo; growth
of distal aorta needing repair by 15 mo
Dieda
Persistent type I or II endoleak at 4 years;
refused further therapy
Alive at 4 y
Aortoesophageal fistula; not open surgical
candidate
Died at 4 mo
Type II endoleak from left subclavian artery
requiring embolization
Died at 3 mo,
cause
unknown
n); IMH, intramural hematoma; PAU, penetrating aortic ulcer; TEVAR,rtic
rage
a
a
a
r (opetery bypass grafting (CABG) and total arch debranching.
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hospital or 30 days of the operative procedure, occurred
in two patients. The first had a short segment TEVAR to
exclude a PAU in the setting of associated IMH, but his
thoracic aorta ruptured the night of surgery. The second
patient underwent TEVAR for a symptomatic 6.3-cm sac-
cular aneurysm that had grown from a pre-existing known
PAU. Her coexisting 5.5-cm infrarenal abdominal aneu-
rysm ruptured on postoperative day 2, and she died despite
immediate open repair. By univariate analysis, only older
age correlated with early mortality (P  .049).
Two patients sustained perioperative stroke. One un-
derwent coverage of the proximal half of the descending
aorta for an asymptomatic growing PAU. The other under-
went concomitant off-pump CABG for left main disease
and total arch debranching for a large PAU with an aneu-
rysm at the innominate artery. He had significant athero-
matous burden in his innominate and left carotid arteries
and sustained multiple embolic events, likely during great
vessel clamping.
There were no instances of permanent paraplegia or
paresis. Two patients did sustain temporary paraplegia. One
responded to immediate placement of a lumbar drain and
permissive hypertension. The other patient, in whom a
drain had been placed, responded to increasing cerebrospi-
nal fluid drainage and further increasing blood pressure.
Transient renal failure needing dialysis occurred in one
patient treated for an infected PAU presenting with a
contained rupture. His renal function returned toward
normal 10 days of his TEVAR.
Late results. At the last follow-up, 14 patients had
died, for a crude mortality rate of 37.8%. The causes of
death included aortic-related causes, comprising thoracic
rupture in 2, abdominal rupture in 1, and aortoesophageal
fistula in 1; myocardial infarction in 1; cancer in 2; cirrhosis
in 1, and an unknown cause in 6. Themedian Kaplan-Meier
survival time of the entire cohort was 89.8 months. On
multivariate analysis, late mortality correlated with an ur-
gent or emergent status of operation (odds ratio, 14.7; P
.007). Kaplan-Meier survival analysis confirmed the time
dependency, with a significant early force of death identi-
fied in those presenting with urgent or emergent operative
status (P  .039 vs elective; Fig 1). Multivariate analysis
also identified treatment with extension into the arch aorta
as protective of late mortality (odds ratio, 0.078; P .011).
Survival analysis stratified by arch repair did not, how-
ever, show any time dependency (P  .1). An analysis to
assess the time to failure of the TEVAR procedure included
the need for open or endovascular aortic reintervention in
the treated or adjacent segments or the occurrence of
thoracic aortic rupture or aortic-related death (Fig 2) and
demonstrated a 5-year actuarial freedom of 81.6%  7.8%.
Details regarding new or persistent endoleaks and late
aortic events in relation to the type of presenting pathology
and the extent of initial therapy are listed in Table II. These
data suggest that failure events occur more frequently in
patients initially treated for PAUwith associated IMH (6 of
9 identified failures of therapy).Late results stratified by presence of IMH. To de-
termine whether differences in PAU pathology were specif-
ically involved in the incidence of treatment failure, we
separated the cohort into two groups by the presence of
associated IMH (ie, PAU vs PAU with IMH). The two
groups were similar in age, prevalence of comorbidities,
frequency of presentation with rupture, or extent of repair
(all P  .12). The only identified variable that differed
between groups was the urgency of the operation (P 
.003). Patients with PAU and IMH had a statistically
significant higher frequency of urgent or emergent inter-
vention (P  .003). A survival curve constructed to com-
pare both groups did not demonstrate a difference in
all-cause mortality based on the presence of an associated
IMH (P  .76, Fig 3, A).
However, a Kaplan-Meier analysis of the efficacy of
Fig 3. Kaplan-Meier analysis shows (A) cumulative survival and
(B) freedom from aortic reintervention, rupture, or aortic-related
mortality for patients with penetrating aortic ulcer (PAU, solid
line) and patients with PAU and intramural hematoma (IMH;
dashed line).TEVAR for PAU stratified by the presence of an associated
JOURNAL OF VASCULAR SURGERY
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associated with an increased risk for treatment failure, de-
fined as the need for open or endovascular aortic reinter-
vention, aortic rupture, or aortic-related death (P  .03;
Fig 3, B).
DISCUSSION
PAUs often occur in the setting of extensive atheroscle-
rotic disease, with the natural history variably described as
malignant or benign.1-7 Tittle et al4 suggested that these
lesions carry a 37% risk for rupture and recommended early
intervention.4 In contrast, Cho et al5 suggested that PAU
in the descending aorta may represent a more benign
clinical entity than originally surmised and recommended a
more selective operative approach, similar to that for the
classic double-barrel acute type B dissection. These re-
ported differences in outcomesmay arise from the inclusion
of ascending aortic PAUs in the study by Tittle et al.
It should be acknowledged, however, that most of the
literature on aortic ulcers is based on imaging features as
found on aortography, CT, or magnetic resonance imaging
rather than on histologic confirmation of an atherosclerotic
etiology of the intimal defect. A lesion that may mimic an
ulcer in its wide communication with the aortic lumen is the
entry or re-entry tear sometimes found in association with
an IMH. Several authors have observed that these tears may
develop along the temporal course of an IMH when the
process is followed for a period of several months.14-16 To
our knowledge, no reports currently describe reliable crite-
ria by which to distinguish a primary penetrating athero-
sclerotic ulcer from the secondary re-entry tear of IMH.
Extensive calcifications in the aortic wall or localized (vs
extensive) dissection may seem to favor an ulcer over a
bland tear, but it is uncertain whether this imaging distinc-
tion reflects a difference of etiology or a varying local
response to the same IMH.
Although the distinction between an ulcer and a bland
tear may seem academic, it is possible that a freely dissecting
aorta may respond differently to an endograft than a rela-
tively dissection-resistant atherosclerotic aorta. In this arti-
cle we have used the term penetrating aortic ulcer to en-
compass the classic atherosclerotic ulcer of Stanson (with or
without IMH) as well as the intimal tears that develop in
the natural history of a “bland” IMH.
Fig 4. This patient illustrates both the principle of TEVAR failure
when performed for PAU with IMH (ie, proximal landing zone),
and also describes the evolution of a new entry tear at the distal
landing zone in the absence of any intervention. He presented with
a PAU and IMH while waiting for repair of a large infrarenal AAA
(A), and underwent treatment of the PAU with a short segment
Talent endograft (B). The stent graft was oversized by 5-10%, and
balloon dilation at the landing zones was avoided. A new entry tear
was identified at the proximal landing zone on a follow-up CT scan
at 30 days (C). Over the ensuing 15months, the patient developed
a new tear at the distal landing zone with growth of the aorta (D at
5 months, and E at 13 months). He eventually expired from
complications of liver failure while awaiting repeat TEVAR.
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incidence primarily in older patients with significant co-
morbidities, has encouraged investigators to treat PAUs
with an endovascular approach.7-11 The present study de-
scribes early and late outcomes for TEVAR for PAU in a
group largely considered high risk for traditional open
repair. Our early results, including 5% rates of death and
stroke and no instances of permanent paraplegia, fare well
compared with previous reports describing mortality rates
of 5% to 15%.7-11 Other investigators have also suggested
an increased in-hospital mortality rate for symptomatic vs
asymptomatic patients.8 Similarly, late death in our study
was independently predicted by the need for an urgent or
emergent indication.
Interestingly, the need for arch repair was identified as
protective on multivariate analysis. A potential hypothesis
could relate to the frequency of late aortic events described
in patients presenting with PAU in other studies. The local
treatment of a PAU occurring in the mid-descending aorta
with a short limited stent graft may leave the distal arch and
proximal descending aorta untreated and thus potentially
still able to dissect, form new aneurysms, or rupture. If the
arch had been treated in this hypothetic patient, the risk for
aortic catastrophe might not exist to a similar extent and
might thus lead to an improved survival. We do not have
sufficient evidence to support this hypothesis in the current
study because our data on the absolute causes of death are
incomplete. Nonetheless, this finding was unexpected and
warrants further study in a larger cohort of patients. Based
on the cumulative experience reported here, however, we
would now advocate for a more extensive treatment, with
coverage extending from the distal arch and descending
aorta to beyond several centimeters of the location of the
PAU.
Despite the localized nature of PAUs, they are fre-
quently seen with associated IMH.1-6 In this setting, the
placement of short-segment stent grafts with landing zones
occurring in friable, unhealthy aortic tissue may compro-
mise the long-term success of this approach. Indeed,
D’Ancona et al11 cautioned against aggressive attempts to
balloon-dilate landing zones to avoid stent graft erosion
into the wall of the aorta. However, we have identified this
to occur at landing zone sites even while oversizing the
device only approximately 5% to 10%, and limiting any
balloon dilatation to the overlap zones between endografts
(Fig 4). As is suggested in Fig 4, the pathology itself, rather
than the technical aspects of the operative procedure, may
lead to late treatment failure. The present study suggests
that although the association of IMH with PAU may not
affect survival, the presence of IMH may limit the late
efficacy of TEVAR for this pathology. Our study is the first,
to our knowledge, to identify the importance of associated
IMH with PAU for TEVAR.
The limitations of this study include its nonrandomized
single-institutional nature and the small sample size. An-
other major limitation is that this study encompasses the
entire TEVAR era at the University of Michigan, with
the use of many different endografts, including custom-fabricated grafts, as well as the evolving technique during
this learning curve. Certain endografts might fare worse in
this setting, as has been suggested in a previous report
describing the incidence of retrograde type A dissection
during TEVAR for acute type B dissection.17However, our
numbers are too small to evaluate for any differences be-
tween endograft types.
As noted earlier, the intimal tears treated in this series
may include both atherosclerotic ulcers and re-entry tears
secondary to IMH, and the different etiology of these tears
may correlate with a variable response to endograft implan-
tation. Finally, the causes of death are not known in all
patients who died and would have been helpful in deter-
mining potential hypotheses for the protective effects of
arch repair identified in this study.
CONCLUSION
TEVAR can be safely accomplished for patients pre-
senting with penetrating aortic ulcers. In this often-debili-
tated and elderly population, thoracic endovascular repair
may be considered the optimal therapy in the setting of
isolated penetrating aortic ulcer. Late outcomes may be
adversely affected by the presence of associated intramural
hematoma. In this setting, the tenets of careful endograft
sizing and an appropriate assessment of the need for imme-
diate therapy vs a delayed approach to allow resolution of
the intramural hematoma may be most important in im-
proving the late efficacy of an endovascular solution for this
pathology.
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